Asieris’ APL-2501 Completes First Patient Enrollment in Clinical Trial for Advanced Solid Tumors

Shanghai, China, September 22, 2026 – Asieris Pharmaceuticals (688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women health with significant unmet medical needs, announced that the first patient has been enrolled in the Phase I/II clinical trial of its independently developed APL-2501 in patients with advanced solid tumors. […] The post Asieris’ APL-2501 Completes First Patient Enrollment in Clinical Trial for Advanced Solid Tumors appeared first on Asieris Pharmaceuticals .